-
Triastek’s 3D-Printed T20G Receives US Clinical Approval for NOAC Treatment
•
China-based Triastek Inc., a pharmaceutical-focused 3D printing company, has announced receiving clinical approval in the US for its T20G. This 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) was previously cleared for trials in China in January of last year. T20G’s Technological AdvantagesT20G leverages Triastek’s patented 3D Microstructure for Gastric Retention…
-
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
•
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical study of its 3D-printed drug product D23, a budesonide ileum-targeted tablet designed to treat IgA nephropathy (IgAN). The study highlights the drug’s precise intestinal targeting and efficacy in addressing the root cause of the disease.…
-
China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
•
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a strategic partnership with Germany’s BioNTech SE (NASDAQ: BNTX), a leading figure in the biopharmaceutical industry. This collaboration aims to leverage Triastek’s cutting-edge 3D drug printing capabilities to develop a breakthrough oral preparation designed to address…
-
Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders
•
Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field…
-
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
•
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed. Triastek utilizes a…
-
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
•
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co.,…
-
Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms
•
China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to explore the application of 3D printing in the development of new chemical entity (NCE) drug dosage forms, although no financial details were disclosed. Triastek’s Technology and…
-
Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery
•
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli Lilly & Co. (NYSE: LLY) to explore 3D printing technology for precise, programmed drug release in the gastrointestinal (GI) tract. Partnership GoalsThe collaboration will focus on two key areas: Triastek’s Technology PlatformTriastek utilizes its MED…
